State biosimilar substitution laws could reduce consumer access and savings
- Collection:
- Health Policy and Services Research
- Series Title(s):
- Fact sheet (AARP Public Policy Institute (Organization))
- Author(s):
- Purvis, Leigh, author McSpadden, James, author
- Contributor(s):
- AARP (Organization), issuing body. Public Policy Institute (AARP (Organization)), issuing body.
- Publication:
- Washington, DC : AARP Public Policy Institute, October 2022
- Language(s):
- English
- Format:
- Text
- Subject(s):
- Biosimilar Pharmaceuticals Cost Savings Health Services Accessibility Legislation, Drug Drug Costs State Government United States
- Genre(s):
- Technical Report
- Abstract:
- Biosimilar drugs are less expensive but equally safe and effective substitutes for expensive biologic drugs. Yet biosimilars that qualify for automatic substitution often have to meet more stringent state substitution requirements than traditional generic drugs. This differential treatment in state laws could contribute to lingering concerns about biosimilars and unnecessarily reduce consumer access to and savings from these increasingly important products.
- Copyright:
- Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY-NC-ND license. (More information)
- Extent:
- 1 online resource (1 PDF file (8 pages)).
- NLM Unique ID:
- 9918557282006676 (See catalog record)
- Permanent Link:
- http://resource.nlm.nih.gov/9918557282006676